cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Emergent Biosolutions Inc
23 own
14 watching
Current Price
$13.99
$0.19
(1.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
124.32M
52-Week High
52-Week High
14.61000
52-Week Low
52-Week Low
1.42000
Average Volume
Average Volume
1.57M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
7.8326
iconMarket Capitalization124.32M
icon52-Week High14.61000
icon52-Week Low1.42000
iconAverage Volume1.57M
iconDividend Yield--
iconP/E Ratio7.8326
What does the Emergent Biosolutions Inc do?
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Read More
How much money does Emergent Biosolutions Inc make?
News & Events about Emergent Biosolutions Inc.
PR Newswire
1 year ago
Thinking about buying stock in Eloxx Pharmaceuticals, Micron Technology, Emergent Biosolutions, Inflarx NV, or TG Therapeutics? Thinking about buying stock in Eloxx Pharmaceuticals, Micron Technology, Emergent Biosolutions, Inflarx NV, or TG Therapeutics? PR Newswire NEW YORK, April 10, 2023 NEW...
Globe Newswire
1 year ago
NARCAN Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening accessExpected over-the-counter availability is anticipated by late summer of this year ...
Globe Newswire
1 year ago
Adds two revenue-generating vaccines for the prevention of cholera and typhoid fever that will establish Bavarian Nordic as a global leader in travel vaccinesBroadens development pipeline with a late-stage Chikungunya vaccine candidate with significant synergistic market opportunity in areas with a ...
Globe Newswire
1 year ago
GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under the...
PR Newswire
1 year ago
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? PR Newswire NEW YORK, Jan. 6, 2023 NEW...
Frequently Asked Questions
Frequently Asked Questions
What is Emergent Biosolutions Inc share price today?
plus_minus_icon
Can Indians buy Emergent Biosolutions Inc shares?
plus_minus_icon
How can I buy Emergent Biosolutions Inc shares from India?
plus_minus_icon
Can Fractional shares of Emergent Biosolutions Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Emergent Biosolutions Inc stocks?
plus_minus_icon
What is today’s traded volume of Emergent Biosolutions Inc?
plus_minus_icon
What is today’s market capitalisation of Emergent Biosolutions Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Emergent Biosolutions Inc?
plus_minus_icon
What percentage is Emergent Biosolutions Inc down from its 52-Week High?
plus_minus_icon
What percentage is Emergent Biosolutions Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.99
$0.19
(1.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.38
$0.08 (6.15 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$18.85
$0.02 (0.11 %)
bluebird bio, Inc.
bluebird bio, Inc.
$1.21
$0.01 (0.83 %)
Xencor Inc
Xencor Inc
$21.63
$0.36 (1.69 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.38
$0.08 (6.15 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$18.85
$0.02 (0.11 %)
bluebird bio, Inc.
bluebird bio, Inc.
$1.21
$0.01 (0.83 %)
Xencor Inc
Xencor Inc
$21.63
$0.36 (1.69 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00